Dose-response relationships for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) suggest a differential sensitivity of liver cell types to the induction of cytochrome P450 gene expression, and that the induction of hepatic protein CYP1A2 causes sequestration of TCDD. In addition, immunolocalization of hepatic CYP1A1/1B1/ 1A2 proteins is not uniform after exposure to TCDD. The mechanism for the regio-specific induction of hepatic P450s by TCDD is unknown, but may involve the differential distribution of participants in the AhR-mediated pathway and/or regional P450 isozymes, as well as, non-uniform distribution/sequestration of TCDD. Therefore, this study examined the effects of TCDD in unfractionated, centrilobular and periportal hepatocytes isolated from female Sprague-Dawley rats acutely exposed (3 days) to a single oral dose of 0.01-10.0 g [ 3 H]TCDD/kg. A dose-dependent increase in concentration of TCDD was accompanied by a dosedependent increase in CYP1A1, CYP1A2, and CYP1B1 mRNA expression and associated enzymes in all liver-cell populations. Centrilobular hepatocytes showed a 2.7-to 4.5-fold higher concentration of TCDD as compared to the periportal hepatocytes at doses up to 0.3 g TCDD/kg. Centrilobular hepatocytes also exhibited an elevated MROD activity as compared to the periportal hepatocytes at doses up to 0.3 g TCDD/kg. Furthermore, centrilobular hepatocytes showed an elevated concentration of induced CYP1A2 and CYP1B1 mRNA as compared to periportal hepatocytes within the 0.01-and 0.3-g TCDD/kg-treatment groups. This is the first study to demonstrate that a dose-dependent difference in distribution of TCDD exists between centrilobular and periportal cells that might be related to regional differences in P450 induction.
The mammalian liver is a heterologous organ composed of 60 -70% parenchymal cells and 30 -40% nonparenchymal cells (Gerhardt, 1992) . The liver lobule represents an anatomical unit that exhibits morphological and biochemical differences within the hepatocyte subpopulations. Many genes, including certain members of the cytochrome P450 superfamily, exhibit a non-uniform or zonated pattern of expression within the liver acinus (Gerhardt, 1992; Gooding et al., 1978) . A greater bioaccumulation of constitutive hepatic cytochrome P450 isozymes occurs in the centrilobular than in the periportal region (Gooding et al., 1978; Lindros, 1997; Oinonen et al., 1994; Oinonen and Lindros, 1998) . For example, constitutive expression of CYP1A2 predominantly localizes to the centrilobular region of liver lysates (Oinonen et al., 1994) . In situ hybridization of CYP1A1 and CYP1A2 mRNA expression also revealed that these genes were differentially expressed across the human liver acinus (McKinnon et al., 1991) . Although parenchymal cells have been presumed to be the major liver cell subpopulation involved in metabolic activation of xenobiotics, drug metabolizing enzymes are also present within the nonparenchymal cell population (Cantrell and Bresnick, 1972) .
Drug metabolism by cytochrome P450s is thought to occur predominantly in the centrilobular hepatocytes (Wanson et al., 1975) . For example, barbiturate-or phenobarbital-administration to female rats resulted in a selective increase in P450 isozymes in the centrilobular hepatocytes as compared to the periportal hepatocytes (Gumucio et al., 1978) . In addition, Western blots and reverse transcriptase-polymerase chain reaction (RT-PCR) studies indicate that a ligand-and dosespecific, zonated expression of CYP1A1 and CYP1A2 genes exists (Oinonen et al., 1994) . Treatment of male Wistar rats The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, NIH. The manuscript has been reviewed in accordance with USEPA policy and approved for publication. However, it does not necessarily reflect the views of the Agency. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.
with 3-methylcholanthrene (3-MC) resulted in a localization of CYP1A1 to the centrilobular hepatocytes, with an even subcellular distribution of CYP1A2 (Oinonen et al., 1994) . In contrast, ␤-naphthoflavone (␤-NF)-treated rats exhibited a periportal regional sequestration of CYP1A1 and CYP1A2 gene expression (Oinonen et al., 1994; Wolf et al., 1984) . These data suggest that there is an uneven distribution of cytochrome P450s throughout liver-cell populations and that chemicalspecific regional localization of cytochrome P450 gene expression may exist.
Dose-response relationships with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in female Sprague-Dawley rats also suggest a differential sensitivity of liver cell types to the induction of CYP1A1, CYP1A2, and CYP1B1 Tritscher et al., 1992; Walker et al., 1998 Walker et al., , 1999 . Immunolocalization of CYP1A1 and CYP1A2 has revealed that distribution of CYP1A1 and CYP1A2 proteins is not uniformly expressed across the liver lobule after subchronic exposure to TCDD (Tritscher et al., 1992) . At low doses of TCDD, CYP1A2 is localized around the central veins. As the TCDD concentration increases, CYP1A2 induction increases to some hepatocytes within the periportal region Tritscher et al., 1992) . In addition, exposure of female Sprague-Dawley rats to 35 ng TCDD/ kg/day for 30 weeks demonstrated that co-localization of CYP1A1, CYP1A2, and CYP1B1 proteins exists within the centrilobular hepatocytes (Walker et al., 1999) . However, CYP1B1 is expressed at lower protein concentrations and exhibits distinct TCDD-induced dose-response relationships as compared to CYP1A1 and CYP1A2 proteins (Santostefano et al., 1997b; Walker et al., 1999) . Collectively, these studies raise the possibility that some hepatocytes may be maximally induced at low doses of TCDD and that all hepatocytes do not exhibit the same dose-response relationships for cytochrome P450 gene expression.
The mechanism for the regio-specific induction of cytochrome P450s in rodent liver, mediated by TCDD and related compounds, is unknown, but may involve the different capacity of specific hepatocyte populations to express P450s regulated by the non-uniform distribution/sequestration of TCDD. Therefore, the current study examined the dose-dependent localization of TCDD in unfractionated, centrilobular and periportal hepatocytes after acute exposure (3 days) of female Sprague-Dawley rats to a single oral dose of 0.01-10.0 g [ 3 H]TCDD/kg and the dose-dependent effects of TCDD on AhR-mediated cytochrome P450 gene expression in isolated hepatic-cell subpopulations. This study demonstrates that a dose-dependent difference in distribution of TCDD exists between centrilobular and periportal cells, which may be related to regional differences in cytochrome P450 induction, resulting in a sequestration of TCDD in centrilobular hepatocytes at low doses.
MATERIALS AND METHODS
Chemicals. 2, 3, 7, H]dibenzo-p-dioxin (specific activity of 34.7 Ci/mmol) was purchased from Chemsyn Science Laboratory (Lenexa, KS). Radiochemical purity (Ն99%) was verified using both a bioassay involving biliary elimination (Kedderis et al., 1991b) , and reverse-phase high pressure liquid chromatography . Unlabeled TCDD (Ն98% stated chemical purity) was obtained from Radian Corp. (Austin, TX). Dosing solutions were prepared by adding a stock of unlabeled TCDD (1 mg/10 ml) in acetone and radiolabeled TCDD (0.91 mCi/ml) in toluene to corn oil. Volatile compounds were removed by evaporation using a Savant SpeedVac (Savant Instruments Inc., Farmingdale, NY) and concentration of [ 3 H]TCDD were determined as described (Santostefano et al., 1996) . All other chemicals used in this study were of the highest grade available from commercial sources.
Animals and treatment.
Female Sprague-Dawley rats (8 weeks; ϳ250 g) were purchased from Charles River Laboratories (Raleigh, NC) and acclimated for one week before dosing. Rats were maintained at the National Health and Environmental Effects Research Laboratory of the U.S. Environmental Protection Agency (Research Triangle Park, NC) and followed a diurnal cycle of 12 h each of light and dark at an ambient temperature of 22 Ϯ 1°C and relative humidity of 55 Ϯ 5%. Animals were placed in polycarbonate cages, each holding 2-3 animals, with hardwood bedding (Beta Chips, North Eastern Products, Inc., Warrensburg, NY). Rats had free access to Purina 5001 Rodent Chow (Ralston Purina Co., St. Louis, MO) and tap water. Rats (n ϭ 3 animals/dose group) received a single oral dose of 0.0 (corn oil), 0.01, 0.1, 0.3, 1.0, or 10.0 g [ 3 H]TCDD/kg at 5 ml/kg body weight (bw) and unfractionated hepatocytes were prepared from individual animals as described below (Kedderis and Held, 1996; Seglen, 1976) 3 days post-treatment. In a separate study, female Sprague-Dawley rats (n ϭ 4 -7 animals/dose group) received a single oral dose of 0.0 (corn oil), 0.01, 0.1, 0.3, 1.0, or 10.0 g [ 3 H]TCDD/kg at 5 ml/kg bw and centrilobular or periportal hepatocytes were prepared from individual animals as described below (Lindros and Penttila, 1985) 3 days post-treatment.
Unfractionated hepatocyte preparation.
Hepatocytes from individual control and TCDD-treated female Sprague-Dawley rats (n ϭ 3 animals/dose group) were isolated as described (Seglen, 1976; Kedderis and Held, 1996) with slight modifications. Rats were anesthetized with pentobarbital (50 mg/kg bw, ip), the peritoneal cavity was opened and the portal vein was cannulated with a 22-gauge Insyte-W I.V. catheter needle unit (Becton Dickinson Vascular Access, Sandy, UT). The vena cava was cut and the liver was perfused in situ at 20 ml/min at 37°C with a predigestion buffer containing 1% Hanks' balanced salt solution (without CaCl 2 , MgCl 2 , MgSO 4 , phenol red and Na 2 HCO 3 ) and supplemented with 23 mM N-[2-hydroxyethyl]piperazine-NЈ-[2-ethanesulfonic acid] (HEPES) and 0.5 mM ethyleneglycol-bis(␤-aminoethyl ether)-N,N,NЈ,NЈ-tetraacetic acid (EGTA) at pH 7.3 under constant oxygen. After 5-10 min , the perfusate was changed to a stock digestion buffer containing 1% Hanks' balanced salt solution (without phenol red and Na 2 HCO 3 ) with 23 mM HEPES, 1.5 mM glycine and 16.65 mM D-fructose at pH 7.3 supplemented with 0.8 mg/ml collagenase D (Boehringer Mannheim, Mannheim, Germany) and continued at 5 ml/min for 5-10 min under constant oxygen at 37°C. The liver was removed and placed in a petri dish containing an ice-cold rinsing buffer comprised of 1% Hanks' balanced salt solution (without phenol red and Na 2 HCO 3 ), 23 mM HEPES and 0.2% BSA at pH 7.3. The liver cells were dispersed into the rinsing buffer by removing the capsule with forceps and employing a gentle combing of the liver. The hepatocyte preparation was filtered through 2 layers of gauze. The hepatocytes were purified by centrifugation at 50 g in an Eppendorf 5804 R centrifuge (Eppendorf-Netheler-Hinz GMBH, Hamburg, Germany) for 1 min at 4°C. The pelleted hepatocytes were resuspended in rinsing buffer, using a wide-bore pipet, and were recentrifuged at 50 g for 1 min at 4°C. The hepatocyte purification process was repeated 3 times. After final centrifugation, unfractionated hepatocytes were resuspended in 50 ml of rinsing buffer and cell viability and number were determined by trypan blue exclusion (Kedderis et al., 1988) . All data are represented as means Ϯ standard deviation. The statistical intergroup comparisons of cell viability and number were determined using a one-way analysis of variance (ANOVA) followed by Scheffe's F-test with p Ͻ 0.01. Hepatocytes were frozen in liquid nitrogen and stored at -80°C until usage. Centrilobular and periportal hepatocyte preparation. Centrilobular and periportal hepatocytes from individual control and TCDD-treated female Sprague-Dawley rats (n ϭ 4 -7 animals/dose group) were isolated by a dual pulse, digitonin-collagenase perfusion system as described (Lindros and Penttila, 1985) with slight modifications. Rats were anesthetized with pentobarbital (50 mg/kg bw, ip), the peritoneal cavity was opened, and the portal vein was cannulated. The upper vena cava was also cannulated via the heart with a 19-gauge needle (Becton Dickinson & Co., Franklin Lakes, NJ). The lower vena cava was cut immediately, and the liver was pre-perfused through the portal vein with a predigestion buffer, at 20 ml/min and 37°C. After 5-10 min, the perfusate was stopped and the lower vena cava was ligated. A 3.5 mM digitonin (ICN Biomedicals, Inc., Aurora, OH) solution, prepared in the predigestion buffer at 100°C, was infused at 37°C through either the upper vena cava or portal vein cannula at a rate of 5 ml/min for the time period necessary (usually 30 -60 s) for a maximal selective destruction pattern to be observed on the liver surface [as described in detail in Lindros and Penttila (1985) ]. Previous studies have illustrated that perfusion of digitonin through the portal vein ruptures the membranes of periportal cells (Lindros, 1997; Lindros and Penttila, 1985; Lindros et al., 1997a,b; Oinonen and Lindros, 1998; Oinonen et al., 1994) . In contrast, perfusion of digitonin through the upper vena cava destroys the centrilobular cells. After stopping the infusion of digitonin, the liver was perfused through the opposite canula to the digitonin solution at 20 ml/min with the predigestion buffer at 37°C under constant oxygen. After 5-10 min, a conventional collagenase digestion method (Kedderis and Held, 1996; Seglen, 1976) was performed via the opposite cannula to the digitonin solution using stock digestion buffer at 5 ml/min for 5-10 min under constant oxygen at 37°C. The liver was removed and centrilobular or periportal hepatocytes were isolated as described above. After final centrifugation, centrilobular or periportal hepatocytes were resuspended in 50 ml of rinsing buffer and cell viability and number were determined by trypan blue exclusion (Kedderis et al., 1988) . All data are represented as means Ϯ standard deviation. The statistical intergroup comparisons of cell viability and number were determined using a one-way ANOVA followed by Scheffe's F-test with p Ͻ 0.01. Centrilobular or periportal hepatocytes were frozen in liquid nitrogen and stored at -80°C until usage. Alanine aminotransferase content, a marker of gene expression in periportal hepatocytes (Ingelman-Sundberg et al., 1988; Lindros and Penttila, 1985; Oinonen et al., 1994) , was determined as described.
Alanine aminotransferase (ALT) activity in periportal and centrilobular hepatocytes. Centrilobular and periportal hepatocyte suspensions were thawed on ice and homogenized with 10 -20 strokes of a Teflon pestle/drill apparatus. The homogenized centrilobular and periportal hepatocyte suspensions were sonicated 2*20 s on ice with 10 s between pulses, using a microson XL ultrasonic cell disruptor (Heat System Inc., Farmingdale, NY). They were then centrifuged at 9000 g for 30 min at 4°C to obtain the supernatant (S9) fraction, using a Beckman model J2-21M induction drive centrifuge with a JA-17 rotor (Beckman Instruments, Fullerton, CA). Protein determination of the centrilobular and periportal hepatocyte S9 fraction was quantified using the method of Bradford (1976) , with BSA as the standard. Alanine aminotransferase activity, a marker of gene expression in periportal hepatocytes (Ingelman-Sundberg et al., 1988; Lindros and Penttila, 1985; Oinonen et al., 1994) , was determined in the S9 fraction obtained from centrilobular and periportal hepatocytes, according to manufacturer recommendations. We used the sample start procedure of the GPT-optimized alanine aminotransferase EC 2.6.1.2 UV-method (Sigma Chemical Co., St. Louis, MO) and water as the reference. Accutrol normal control serum standard (Sigma Chemical Co., St. Louis, MO) was used to assess reliability of the assay. Alanine aminotransferase (ALT) activity is expressed as units/mg protein. All data are represented as means Ϯ standard deviation. The statistical intergroup comparisons within each liver-cell population across the different doses of TCDD were determined using a one-way ANOVA followed by Scheffe's F-test with p Ͻ 0.05. An unpaired 2-tailed t-test was used to statistically compare the ALT activity in periportal cells and centrilobular hepatocytes within the same treatment group.
Determination of TCDD-derived radioactivity. Previous studies from this laboratory indicate that more than 95% [
3 H]TCDD present in tissues is recovered as parent compound (Kedderis et al., 1991a) . The concentration of [ 3 H]TCDD in the tissue was determined by sample combustion as described (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) Triplicate samples of freshly isolated, unfractionated centrilobular and periportal hepatocytes (200 mg) were combusted. A piece of hepatic tissue was not removed in order to prevent a possible deficiency in tissue perfusion and/or hepatocyte isolation. However, triplicate samples of adipose tissue (50 mg) were combusted to determine TCDD concentration as a means to compare tissue dose in these studies to previous studies using this dosing regimen (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) . Adipose tissue content was defined by whole body dissection and was 7% as described (Santostefano et al., 1996) . As with previous studies (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) , similar adipose tissue concentrations of TCDD were observed (data not shown). The concentration of TCDD in unfractionated, centrilobular and periportal hepatocytes is expressed as attograms (ag) TCDD/viable hepatocyte based upon cell number and viability as determined by trypan blue exclusion. The concentration of TCDD found in the unfractionated cells (expressed as ng TCDD/ total tissue) was also calculated based upon 128 ϫ 10 6 hepatocytes/g liver (Seglen, 1976) . We estimated the liver weight in these studies from a percentage of the body weight. TCDD causes hepatomegaly with increasing dosage Pegram et al., 1995) . Thus, a slight increase in the percent liver/body weight ratio with increasing dose was used to estimate the weight of the liver using data obtained in previous studies (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) . The data are represented as means Ϯ standard deviation. The statistical intergroup comparisons were determined across the different doses of TCDD using a one-way ANOVA followed by Fisher's PLSD test with p Ͻ 0.05. A log 10 transformation was utilized to normalize the concentration of TCDD in isolated liver-cell populations. An unpaired 2-tailed t-test was performed in order to statistically compare the concentration of TCDD in periportal and centrilobular hepatocytes within the same treatment group.
Enzymatic assays for CYP1A1 and CYP1A2 gene expression. Ethoxyresorufin, methoxyresorufin, and resorufin were purchased from Molecular Probes (Eugene, OR). Microsomal ethoxyresorufin O-deethylase (EROD) and methoxyresorufin O-demethylase (MROD) activities, markers for CYP1A1 (Pohl and Fouts, 1980) and CYP1A2 gene expression (Chaloupka et al., 1995) , were quantitated in unfractionated, centrilobular, and periportal hepatocytes essentially as described Santostefano et al., 1996) . EROD or MROD activity is calculated as pmoles/min/mg microsomal protein. All data are represented as means Ϯ standard deviation. The statistical intergroup comparisons were determined across the different doses of TCDD using a one-way ANOVA followed by Fisher's PLSD test with p Ͻ 0.05. An unpaired 2-tailed t-test was used for a statistical comparison of the EROD and MROD activity in periportal cells and centrilobular hepatocytes within the same treatment group.
Quantitative RT-PCR for determination of CYP1A1, CYP1A2, and CYP1B1 mRNA expression. Quantitation of mRNA expression was determined using a competitive RT-PCR titration method as described (Vanden Heuvel et al., 1993 , 1994 using RNA-specific internal standards. This method has been published in detail elsewhere (Vanden Heuvel et al., 1993 , 1994 Walker et al., 1999) . The data is expressed as copies/100 ng RNA. All data are represented as means Ϯ standard deviation. The statistical intergroup comparisons were determined across the different doses of TCDD using a one-way ANOVA followed by Fisher's PLSD test with p Ͻ 0.05. An unpaired 2-tailed t-test was used to statistically compare P450 mRNA expression in periportal and centrilobular hepatocytes within the same treatment group.
RESULTS

Isolation and Characterization of Unfractionated, Centrilobular and Periportal Hepatocytes
Examination of the isolated liver cells for ALT activity, a marker of periportal hepatocytes, showed an approximate 3-fold elevation in ALT activity in periportal cells (0.29 Ϯ 0.07 units/mg protein) when compared to centrilobular cells (0.11 Ϯ 0.02 units/mg protein), which was unaffected by a dose of TCDD (data not shown). As with previous studies (Lindros and Penttila, 1985; Oinonen et al., 1994) , the periportal dominance of ALT activity was observed indicating a zone selectivity of isolated cell populations using the dual pulse digitonin-collagenase perfusion system. Glutathione reductase activity, a marker enzyme, evenly distributed between centrilobular and periportal cells , was similar in centrilobular (23 Ϯ 8 units/mg protein) and periportal (21 Ϯ 5 units/mg protein) hepatocytes obtained from control animals. Gamma glutamyl transferase, a marker enzyme elevated in hepatocytes from the periportal origin (Lindros and Penttila, 1985) , was higher in periportal hepatocytes (0.37 Ϯ 0.14 units/mg protein) as compared to centrilobular cells (0.15 Ϯ 0.05 units/mg protein). Centrilobular hepatocytes prepared from control-and TCDD-treated animals had an average cell viability of 66.9 Ϯ 6.4% and cell yield was 1.5 Ϯ 0.8 ϫ 10 6 viable hepatocytes/ ml. Periportal hepatocytes prepared from control-and TCDDtreated animals had an average cell viability of 70.0 Ϯ 5.7% and cell yield was 2.0 Ϯ 0.7 ϫ 10 6 viable hepatocytes/ml. Unfractionated hepatocytes prepared from control and TCDDtreated animals had an average cell viability of 70.9 Ϯ 3.5% and cell yield was 2.3 Ϯ 0.5 ϫ 10 6 viable hepatocytes/ml. In addition, there was no effect of TCDD on cell viability or yield in unfractionated, centrilobular or periportal hepatocytes (data not shown).
Localization of TCDD in Isolated Centrilobular and
Periportal Hepatocyte Populations Table 1 shows the dose-dependent localization of TCDD in unfractionated, centrilobular and periportal hepatocytes isolated from TCDD-treated female Sprague-Dawley rats at 3 days following a single exposure to TCDD. A dose-dependent increase in the concentration of TCDD (ag TCDD/viable he- patocyte) was observed in all liver-cell populations across the dose range tested (Table 1) . Examination of the concentration of TCDD found within the unfractionated hepatocytes prepared from female Sprague-Dawley rats exposed to a single oral dose of 10 g TCDD/kg based upon an estimated liver weight and using 128 ϫ 10 6 hepatocytes/g liver (Seglen, 1976) resulted in a localization of 3694 Ϯ 1109 ng TCDD/total tissue in the liver 3-days post treatment. Figure 1 shows a comparison of the dose-dependent differences in localization of TCDD in centrilobular and periportal hepatocytes. The concentration of TCDD (ag TCDD/viable hepatocyte) was significantly higher (2.7-4.5-fold) in centrilobular cells as compared to periportal hepatocytes at doses up to 300 ng TCDD/kg (0.3 g TCDD/ kg). A similar concentration of TCDD was found within the centrilobular and periportal hepatocytes prepared from animals treated with 1000 or 10,000 ng TCDD/kg ( Fig. 1 and Table 1 ).
Dose-Dependent Effects of TCDD on EROD and MROD Activities in Isolated Liver-Cell Populations
Table 1 also shows the dose-dependent effects of TCDD on EROD and MROD activities in unfractionated, centrilobular, and periportal hepatocytes isolated from control and TCDDtreated female Sprague-Dawley rats at 3 days following a single exposure to TCDD. A dose-dependent increase in TCDD-induced EROD and MROD activity was also observed in all liver-cell populations across the dose-range tested (Table  1) . Maximum EROD activity was found in unfractionated, centrilobular, and periportal hepatocytes obtained from rats treated with 10.0 g TCDD/kg. The highest MROD activity was found in unfractionated hepatocytes prepared from rats treated with 10.0 g TCDD/kg. In contrast, centrilobular and periportal hepatocytes reached a maximal inducibility of MROD activity after exposure to doses of 1.0 g TCDD/kg and above. Higher basal EROD and MROD activities were found in centrilobular cells, as compared to periportal hepatocytes (Table 1 ). In addition, a higher level of TCDD-induced EROD and MROD activities were observed in centrilobular cells, as compared to periportal hepatocytes at doses up to 0.3 g TCDD/kg (Table 1) . However, TCDD-induced EROD and MROD activities were similar in centrilobular and periportal hepatocytes prepared from animals treated with 1.0 or 10.0 g TCDD/kg (Table 1) . Figure 2 shows a correlation of the dose-dependent localization of TCDD and TCDD-induced effects on MROD activities in centrilobular and periportal hepatocytes (r 2 ϭ 0.79). At doses up to 0.3 g TCDD/kg, the higher concentration of TCDD within centrilobular hepatocytes was associated with an elevation of TCDD-induced MROD activity in centrilobular hepatocytes compared to periportal cells. Within the 1.0-and 10.0-g TCDD/kg treatment groups, a similar concentration of 3 H]TCDD in each liver-cell population was determined by sample combustion as described (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) and is expressed as ag [ 3 H]TCDD/viable hepatocyte. MROD activity, a marker for CYP1A2 gene expression (Chaloupka et al., 1995) , was quantitated spectrofluorimetrically as described Santostefano et al., 1996 Santostefano et al., , 1998 and expressed as pmoles/min/mg microsomal proteins. Data are presented for hepatic cell populations obtained from individual animals (n ϭ 4 -7 animals/dose group). Also shown is the logarithmic fit of the relationship of MROD activity with hepatocyte concentration of TCDD (solid-line, y ϭ 0.17Ln(x) ϩ 1.67; r 2 ϭ 0.79).
FIG. 1.
Dose-dependent localization of TCDD in isolated hepatocytes. Centrilobular and periportal hepatocytes from control-and TCDD-treated female Sprague-Dawley rats were isolated as described in the Materials and Methods section. The concentration of [ 3 H]TCDD in each liver-cell population was determined by sample combustion as described (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) and is expressed as ag 
-tailed t-test).
TCDD was observed within both centrilobular and periportal hepatocytes, which resulted in similar effects on TCDD-induced MROD activities within both cell types. Table 2 shows the dose-dependent effects of TCDD on CYP1A1, CYP1B1, and CYP1A2 mRNA expression in unfractionated, centrilobular, and periportal hepatocytes isolated from control and TCDD-treated female Sprague-Dawley rats at 3 days following a single exposure to 0.01, 0.3, or 10.0 g TCDD/kg as determined by quantitative RT-PCR. In all isolated hepatic cell populations, the TCDD-induced mRNA expression (copies/100 ng RNA) displayed the pattern: CYP1A2 Ͼ CYP1A1 ϾϾ CYP1B1 (Table 2) . A dose-dependent increase in TCDD-induced CYP1A1, CYP1B1, and CYP1A2 mRNA expression was observed in unfractionated and centrilobular hepatocytes prepared from animals treated with 0.01, 0.3, or 10.0 g TCDD/kg (Table 2) . A dosedependent increase in TCDD-induced CYP1A1 and CYP1A2 mRNA expression was found within periportal hepatocytes (Table 2 ). In contrast, TCDD-induced CYP1B1 mRNA expression in periportal hepatocytes was near the limit of detection (Ͻ10 2 copies/100 ng RNA) in animals treated with 0.01 or 0.3 g TCDD/kg. However, a dramatic increase in TCDD-induced CYP1B1 mRNA expression was observed in periportal hepatocytes isolated from female Sprague-Dawley rats treated with 10.0 g TCDD/kg. A non-significant reduction (3-fold) in ␤-actin mRNA expression was found within unfractionated hepatocytes prepared from the 10.0 g-TCDD/kg treatment group as compared to untreated animals. In addition, a statistically significant dose-dependent reduction (2-3-fold) in ␤-actin mRNA expression was also found in centrilobular and periportal hepatocytes prepared from TCDD-treated animals (data not shown). Table 2 also shows a comparison of the dose-dependent effects of TCDD on CYP1A1, CYP1B1, and CYP1A2 mRNA expression in centrilobular and periportal hepatocytes as determined by quantitative RT-PCR. An elevated basal CYP1A1 and CYP1A2 mRNA expression were observed within centrilobular cells when compared to periportal hepatocytes. In contrast, constitutive CYP1B1 mRNA expression in centrilobular and periportal hepatocytes was below the detection limits of the assay (Ͻ10 2 copies/100 ng RNA). An increase in TCDD-induced CYP1A1 mRNA expression was observed in centrilobular cells as compared to periportal hepatocytes prepared from animals treated with 0.01 g TCDD/kg (Table 2 ). An even zonation of TCDD-induced CYP1A1 mRNA expression was found in centrilobular and periportal hepatocytes within the 0.3 and 10.0 g TCDD/kg treatment groups (Table  2 ). In contrast, TCDD-induced CYP1A2 and CYP1B1 mRNA expression was elevated in centrilobular cells as compared to periportal hepatocytes prepared from animals treated with 0.01 and 0.3 g TCDD/kg (Table 2) . A uniform zonation of TCDDinduced CYP1A2 and CYP1B1 mRNA expression was found in centrilobular and periportal hepatocytes isolated from female Sprague-Dawley rats treated with 10.0 g TCDD/kg (Table 2) . Figure 3 shows a comparison of the dose-dependent localization of TCDD and TCDD-induced effects on CYP1A2 mRNA expression in centrilobular and periportal hepatocytes (r 2 ϭ 0.91). At doses up to 0.3 g TCDD/kg, the elevated concentration of TCDD (ag TCDD/viable hepatocyte) within centrilobular hepatocytes was associated with an elevated concentration (copies/100 ng RNA) of TCDD-induced CYP1A2 mRNA expression in centrilobular hepatocytes as compared to periportal cells. Within the 10.0 g TCDD/kg treatment groups, a similar concentration of TCDD was observed within both centrilobular and periportal hepatocytes that resulted in similar effects on TCDD-induced CYP1A2 mRNA expression within both cell types.
Dose-Dependent Effects of TCDD on CYP1A1, CYP1A2, and CYP1B1 mRNA Expression in Isolated Liver Cell Populations
DISCUSSION
Previous studies, using dose-response relationships for TCDD and related polyhalogenated aromatic hydrocarbons (PHAHs), have developed PBPK and PD models for tissue distribution and enzyme induction in rats and mice (Andersen and Greenlee, 1991; Andersen et al., 1993; Kedderis et al., 1993; King et al., 1983; Kohn et al., 1993 Kohn et al., , 1996 Leung et al., 1988 Leung et al., , 1990a Roth et al., 1993 Roth et al., , 1994 Santostefano et al., 1998; Wang et al., 1997) . Collectively, these studies assume that the induction of the TCDD-binding protein (CYP1A2) is the mechanism for hepatic sequestration of TCDD Diliberto et al., 1995 Diliberto et al., , 1997 Poland et al., 1989a,b; Santostefano et al., 1996 Santostefano et al., , 1997a Santostefano et al., , 1998 Tritscher et al., 1992; Aust, 1987, 1989) . This was confirmed by studies using CYP1A2 knockout mice . These studies all treat the liver as a homogenous cell population. However, dose-response relationships after exposure to TCDD indicate a nonuniform hepatic immunolocalization of CYP1A1, CYP1B1, and CYP1A2 Tritscher et al., 1992; Walker et al., 1998 Walker et al., , 1999 . Thus, recent multicompartmental geometric liver PBPK modeling studies have been developed (Andersen et al., 1997a,b) utilizing the immunohistochemical localization of CYP1A1 and CYP1A2 coupled with hepatic tissue burdens of TCDD (Abraham et al., 1988; Tritscher et al., 1992) . The heterogeneous model describes the regional distribution of TCDD and subsequent effects on gene expression based on centrilobular to periportal geometric distribution of TCDD and induced protein expression with CYP1A2 as the hepatic ligand-inducible binding species for TCDD. This heterogeneous PBPK model developed by Andersen et al. (1997a,b) suggests that the doseresponse curves for TCDD-induced gene expression vary in hepatic zones. Thus, hepatic regional-specific ED 50 values for AhR-mediated responses are obtained. However, the geometric PBPK model is based upon a hypothesis that regional differences in sensitivity (P450 induction) to dose exist within the liver, mediated by molecular switches between states of P450 expression (on/off) due to regional TCDD concentration. To test this hypothesis, the hepatic localization of TCDD in unfractionated, centrilobular, and periportal hepatocytes and effects of TCDD on AhR-mediated cytochrome P450 gene expression in isolated hepatic cell subpopulations was examined. Table 1 shows a dose-dependent increase in localization of TCDD in unfractionated hepatocytes isolated from TCDDtreated female Sprague-Dawley rats at 3 days following a single exposure to 0.01-10.0 g [ 3 H]TCDD/kg. A time-dependent increase in localization of TCDD in parenchymal cells (unfractionated hepatocytes) has also been observed (Hakansson and Hanberg, 1989; Olson et al., 1994; Shen and Olson, 1987) . Extrapolation of ag TCDD/unfractionated hepatocyte (Table 1) to a ng TCDD/total tissue basis, using an estimation of liver weight and number of hepatocytes/g liver (as described in the Materials and Methods section) showed a similar trend in the dose-dependent increase in localization of TCDD in unfractionated hepatocytes to that observed in previous wholeliver disposition studies for TCDD, using similar dosing regimens (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) . For example, acute exposure of female Sprague-Dawley rats treated with a single oral dose of 10 g TCDD/kg resulted in localization of 918 Ϯ 168 ng TCDD/total tissue in homoge- 3 H]TCDD in each liver-cell population was determined by sample combustion as described (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) and is expressed as ag [
3 H]TCDD/viable hepatocyte. Quantitation of CYP1A2 mRNA expression was determined using a competitive RT-PCR titration method as described (Vanden Heuvel et al., 1993 , 1994 Walker et al., 1999) and expressed as copies/100 ng RNA. Data are presented for hepatic cell populations obtained from individual animals (n ϭ 4 -7 animals/dose group). Also shown is the logarithmic fit of the relationship between CYP1A2 mRNA expression and hepatocyte concentration of TCDD (solid-line, y ϭ 0.21Ln(x) ϩ 6.57; r 2 ϭ 0.91).
nized liver 3 days post-treatment (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) . Examination of the concentration of TCDD found within the unfractionated, viable hepatocyte population prepared from female Sprague-Dawley rats, when exposed to a single oral dose of 10 g TCDD/kg based upon an estimated liver weight, and using 128 ϫ 10 6 hepatocytes/g liver (Seglen, 1976) , resulted in a localization of 3694 Ϯ 1109 ng TCDD/total tissue in the liver 3 days posttreatment. In addition, a similar percentage of administered dose of TCDD/total liver tissue was found within unfractionated hepatocytes, as had been observed with other whole liver disposition studies (Santostefano et al., 1996 (Santostefano et al., , 1997b Wang et al., 1997) and hepatocyte isolation studies (Hakansson and Hanberg, 1989) , using Sprague-Dawley rats exposed to 10 g TCDD/kg. The overestimation of the concentration of TCDD found in the unfractionated, viable hepatocyte population, when extrapolating to whole liver, may be due to the additional distribution of TCDD within non-viable hepatocytes, as well as the nonparenchymal cell population.
The best characterized of the TCDD-induced biochemical responses are the induction of CYP1A1, CYP1A2, and CYP1B1 gene expression (Birnbaum, 1994; Hankinson, 1995; Safe, 1986; Whitlock, Jr., 1993; Whitlock, Jr. et al., 1996) . A dose-dependent increase in TCDD-induced cytochrome P450 gene mRNA expression (Table 2) and TCDD-induced EROD and MROD activity (Table 1) were observed in unfractionated hepatocytes across the dose-range tested. The dose-response relationships for TCDD-induced CYP1A1, CYP1A2, and CYP1B1 mRNA expression in unfractionated hepatocytes (Table 2) were similar to previous whole-liver tissue studies (Vanden Heuvel et al., 1994; Walker et al., 1998 Walker et al., , 1999 . Quantitative RT-PCR also demonstrated that CYP1B1 mRNA is expressed at lower concentrations and exhibits different TCDD-induced dose-response relationships than CYP1A1 and CYP1A2 mRNA expression using unfractionated hepatocytes ( Table 2) . The latter were similar to effects observed on TCDD-induced cytochrome P450 protein expression using liver microsomes (Santostefano et al., 1997b; Walker et al., 1998 Walker et al., , 1999 . In contrast, the absolute values for TCDD-induced EROD and MROD activities (pmoles/min/mg microsomal protein) in female Sprague-Dawley rats acutely exposed (3 days) to 0.01-10.0 g TCDD/kg were lower in unfractionated hepatocytes (Table 1) in liver tissue homogenates (Santostefano et al., 1996 (Santostefano et al., , 1998 or precision-cut liver slices (Drahushuk et al., 1996) prepared from TCDD-treated rats. However, a similar trend in the dose-dependent increase in TCDD-induced CYP1A1-and CYP1A2-dependent enzymatic activities was observed (see Table 1 and Drahushuk et al., 1996; Santostefano et al., 1996 Santostefano et al., , 1998 . Although parenchymal cells have been presumed to be the major liver cell subpopulation involved in metabolic activation of xenobiotics, drug metabolizing enzymes are also present within the nonparenchymal cell population (Cantrell and Bresnick, 1972) . For example, adult male rats treated with 3-MC exhibited a 17-fold increase in benzpyrene (B[a]P) hydroxylase activity in nonparenchymal cells and 6-fold increase in B[a]P hydroxylase activity in parenchymal cells. Thus, the higher absolute TCDD-induced enzymatic activities in microsomes prepared from a tissue homogenate may be due in part to the presence of drug metabolizing enzymes in both parenchymal and nonparenchymal cell fractions.
Accumulation of TCDD within specific hepatic cell populations has been demonstrated (Hakansson and Hanberg, 1989) . For example, stellate cells (a type of nonparenchymal cell) exhibit an elevated concentration of TCDD (percent administered dose/cell) as compared to unfractionated hepatocytes prepared from TCDD-treated male Sprague-Dawley rats (Hakansson and Hanberg, 1989) . However, previous studies (Abraham et al., 1988; Kedderis et al., 1993; Diliberto et al., 1995; Kociba et al., 1978; Kociba and Schwetz, 1982; Poiger et al., 1989; Santostefano et al., 1996; Shen and Olson, 1987; Wang et al., 1997) , did not examine the dose-dependency of regional localization of TCDD within isolated hepatocyte populations (centrilobular and periportal). Table 1 demonstrates a dose-dependent localization of TCDD within both centrilobular and periportal cells isolated from female Sprague-Dawley rats acutely exposed (3 days) to a single oral dose of 0.01-10.0 g TCDD/kg. However, some dose-dependent differences in localization of TCDD were observed within individual hepatocyte populations. For example, a statistically significant (p Ͻ 0.05) increase in the concentration of TCDD (ag TCDD/viable hepatocyte) was observed in centrilobular cells as compared to periportal hepatocytes at doses up to 300 ng TCDD/kg (0.3 g TCDD/kg; Fig. 1 and Table 1 ). This is the first study to demonstrate that a dose-dependent difference in regional distribution of TCDD exists within the liver lobule, namely in centrilobular and periportal hepatocytes, after acute exposure to TCDD.
Previous studies have indicated that there is a non-uniform pattern of cytochrome P450 gene expression across the liver lobule Lindros, 1997; Oinonen et al., 1998; Tritscher et al., 1992; Walker et al., 1998 Walker et al., , 1999 . Table 1 demonstrates that a dose-dependent increase in TCDD-induced CYP1A1, CYP1A2, and CYP1B1 mRNA expression and in TCDD-induced EROD and MROD activities exists within both centrilobular and periportal hepatocytes obtained from female Sprague-Dawley rats acutely exposed (3 days) to 0.01-10.0 g TCDD/kg. However, some dose-dependent differences in TCDD-induced cytochrome P450 mRNA expression and associated enzymatic activities were observed within specific cell populations (Tables 1 and 2 and Figs. 2 and 3) . For example, a statistically significant (p Ͻ 0.05) increase in EROD and MROD activities were observed in centrilobular cells as compared to periportal hepatocytes at doses up to 0.3 g TCDD/kg (Table 1 ). In addition, TCDD-induced CYP1A2 and CYP1B1 mRNA expression was elevated in centrilobular cells as compared to periportal hepatocytes prepared from animals treated with 0.01 and 0.3 g TCDD/kg (Table 2) . In contrast, an increase in TCDD-induced CYP1A1 mRNA expression was only observed in centrilobular cells as compared to periportal hepatocytes prepared from animals treated with 0.01 g TCDD/kg (Table 2) . These data correlate with previous studies showing that TCDD-induced CYP1A1, CYP1B1, and CYP1A2 protein expression is not uniformly expressed across the liver lobule after subchronic exposure to TCDD Tritscher et al., 1992; Walker et al., 1998 Walker et al., , 1999 .
Many studies have shown a correlation between the hepatic concentration of TCDD and TCDD-induced CYP1A1 and CYP1A2 protein expression (DeVito et al., 1994; Santostefano et al., 1998; Tritscher et al., 1992; Walker et al., 1999) . However, the correlation between the dose-dependent localization of TCDD and TCDD-induced enzymatic activities in isolated liver-cell populations has not previously been examined. Figures 2 and 3 demonstrate that the higher concentration of TCDD within centrilobular hepatocytes results in an elevation of TCDD-induced CYP1A2 mRNA expression (Fig. 3 ) and MROD activity (Fig. 2) in centrilobular hepatocytes as compared to periportal cells. However, a similar concentration of TCDD within both centrilobular and periportal hepatocytes results in similar effects on TCDD-induced CYP1A2 mRNA expression (Fig. 3) and MROD activity (Fig. 2) within both cell types. These data support the hypothesis, used in the geometric liver model for TCDD (Andersen et al., 1997a,b) , that regional hepatic differences in P450 induction exist across the liver lobule mediated by the concentration of TCDD. An alternate hypothesis may be that there is a multifactorial basis, such as differences in oxygen gradients and/or differences in regulatory proteins across the liver, which is responsible for the differential zonal expression of P450s. For example, recent studies suggest that the selective localization of the AhR within centrilobular cells may be responsible for the preferential localization of P450 gene expression observed in centrilobular hepatocytes (Forkert, 1997; Lindros et al., 1997b) . However, other studies suggest a more uniform distribution of the AhR across the liver lobule (Abbott et al., 1995; Willey et al., 1998) and recent PBPK models demonstrate that CYP1A2 induction is the major determinant for hepatic sequestration of TCDD and related compounds Wang et al., 1997) . For example, Wang et al. (1997) found an unreasonable equilibrium distribution ratio for TCDD localization if CYP1A2 induction is removed. In addition, Kedderis and coworkers (1993) showed that PBPK models are highly sensitive to the binding affinity of the ligand for CYP1A2 and that the inclusion of endogenous substrates to competitively compete for CYP1A2 could result in decreased hepatic localization of ligand in relation to time and dose. Moreover, dose-response studies demonstrate that the hepatic concentration of ligand exceed that found within the adipose tissue due to the induction of CYP1A2 Wang et al., 1997) . Collectively, Figures 2 and 3 indicate a gradient of TCDD localization across the liver lobule mediated by the induction of CYP1A2.
In summary, these data show that centrilobular and periportal hepatocytes exhibit differences in TCDD localization and the induction of cytochrome P450 gene expression. In addition, this is the first study to demonstrate that the dose-dependent increase in the concentration of TCDD within a specific hepatocyte population correlates with CYP1A2 mRNA expression and MROD activity. This finding implies that hepatic regional differences in localization of TCDD may be due to an interaction of TCDD with CYP1A2, resulting in a sequestration of TCDD in centrilobular hepatocytes at low doses. Recently, studies from this laboratory demonstrated that hepatic microsomal sequestration of TCDD does not occur in male CYP1A2 (-/-) mice, also supporting the role of CYP1A2 as the microsomal binding protein involved in TCDD sequestration in the liver Santostefano et al., 1997a) . Thus, this data may provide further insight into the mechanism of sequestration of TCDD within specific regions of the liver. In addition, these data can be used to validate the tissue-specific predictions made in the multi-compartmental liver model proposed by Andersen and colleagues (Andersen et al., 1997a,b) , which may aid in the application of tissue-specific compartments within mechanistic PBPK and PD models for use in human risk assessment of TCDD and related compounds.
